Status:

UNKNOWN

The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in Children With Ulcerative Colitis

Lead Sponsor:

Children's Hospital Los Angeles

Conditions:

Ulcerative Colitis

Eligibility:

All Genders

7-21 years

Phase:

PHASE1

Brief Summary

Ninety Six patients with mild to moderate ulcerative colitis will be randomized to double blind, placebo controlled study. The safety and efficacy of the intervention will be closely monitored.

Detailed Description

The enteric microbiota is now accepted as an important etiologic factor in the pathogenesis of human Inflammatory Bowel Disease (IBD) and immune-mediated chronic experimental intestinal inflammation, ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Age: 7-21 who have been diagnosed with ulcerative colitis
  • Mild to moderate disease based on PUCAI with a score of 10-64
  • Need for colonoscopy
  • Exclusion Criteria
  • Children who are known to be resistant to steroid therapy, immunomodulators and biologics, or on a steroid dose greater than 0.5 mg/kg/day (maximum 20 mg)
  • Children with recent dose change of biologics (within 4 weeks), 5-ASA, steroids or immunomodulators (within 4 weeks)
  • Allergy to or intolerance of mesalamine or 5-ASA products
  • Any evidence of infectious colitis
  • Concurrent infections that require anti-microbial therapy (such as abdominal abscess, pneumonia, etc…)
  • Unable to give informed consent/assent
  • Have received probiotic preparations ≤ 4 weeks prior to randomization
  • Pregnancy and breast feeding in patient subjects of childbearing potential
  • Subjects with significant renal and liver dysfunction (creatinine \> 2 mg/dl and direct bilirubin \> 2 mg/dl), Subjects with congenital or acquired immunodeficiency, or who are immunosuppressed due to conditions other than ulcerative colitis (such as neoplastic disease or organ transplantation), have received or are receiving chemotherapy, or have been diagnosed with HIV.

Exclusion

    Key Trial Info

    Start Date :

    November 1 2016

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    November 1 2023

    Estimated Enrollment :

    101 Patients enrolled

    Trial Details

    Trial ID

    NCT02291523

    Start Date

    November 1 2016

    End Date

    November 1 2023

    Last Update

    November 2 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Children's Hospital Los Angeles

    Los Angeles, California, United States, 90027